Diligence memo · auto-generated · as of July 2, 2026

Firm Of John Dickinson Schneider Inc

Firm Of John Dickinson Schneider Inc looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Firm Of John Dickinson Schneider Inc operates in Other Health Care, based in LIBERTYVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Firm Of John Dickinson Schneider Inc has raised $34M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $16M on 2023-06-30.

Most recent recorded round closed around 2023-06-30.

Valuation (modeled)modeled

Provath models Firm Of John Dickinson Schneider Inc at approximately $145M (range $38M–$314M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.95× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 3.0 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 2.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 89% of Other Health Care peers (5377 compared).

Modeled value ranks above 85% of those peers.

Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.